» Articles » PMID: 35745806

Increased/Targeted Brain (Pro)Drug Delivery Via Utilization of Solute Carriers (SLCs)

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2022 Jun 24
PMID 35745806
Authors
Affiliations
Soon will be listed here.
Abstract

Membrane transporters have a crucial role in compounds' brain drug delivery. They allow not only the penetration of a wide variety of different compounds to cross the endothelial cells of the blood-brain barrier (BBB), but also the accumulation of them into the brain parenchymal cells. Solute carriers (SLCs), with nearly 500 family members, are the largest group of membrane transporters. Unfortunately, not all SLCs are fully characterized and used in rational drug design. However, if the structural features for transporter interactions (binding and translocation) are known, a prodrug approach can be utilized to temporarily change the pharmacokinetics and brain delivery properties of almost any compound. In this review, main transporter subtypes that are participating in brain drug disposition or have been used to improve brain drug delivery across the BBB via the prodrug approach, are introduced. Moreover, the ability of selected transporters to be utilized in intrabrain drug delivery is discussed. Thus, this comprehensive review will give insights into the methods, such as computational drug design, that should be utilized more effectively to understand the detailed transport mechanisms. Moreover, factors, such as transporter expression modulation pathways in diseases that should be taken into account in rational (pro)drug development, are considered to achieve successful clinical applications in the future.

Citing Articles

Advancing Central Nervous System Drug Delivery with Microtubule-Dependent Transcytosis of Novel Aqueous Compounds.

Zhang M, Zhong S, An L, Xiang P, Hu N, Huang W Biomater Res. 2024; 28:0051.

PMID: 39050687 PMC: 11268840. DOI: 10.34133/bmr.0051.


Overcoming Barriers in Glioblastoma-Advances in Drug Delivery Strategies.

Ter Linden E, Abels E, van Solinge T, Neefjes J, Broekman M Cells. 2024; 13(12.

PMID: 38920629 PMC: 11201826. DOI: 10.3390/cells13120998.


Advanced Blood-Brain Barrier Drug Delivery.

Pardridge W Pharmaceutics. 2023; 15(1).

PMID: 36678722 PMC: 9866552. DOI: 10.3390/pharmaceutics15010093.

References
1.
Pliszka M, Szablewski L . Glucose Transporters as a Target for Anticancer Therapy. Cancers (Basel). 2021; 13(16). PMC: 8394807. DOI: 10.3390/cancers13164184. View

2.
Gallagher-Colombo S, Maminishkis A, Tate S, Grunwald G, Philp N . Modulation of MCT3 expression during wound healing of the retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2010; 51(10):5343-50. PMC: 3066603. DOI: 10.1167/iovs.09-5028. View

3.
Choi K, Zhuang H, Crain B, Dore S . Expression and localization of prostaglandin transporter in Alzheimer disease brains and age-matched controls. J Neuroimmunol. 2008; 195(1-2):81-7. PMC: 2365511. DOI: 10.1016/j.jneuroim.2008.01.014. View

4.
Bagchi S, Baomar H, Al-Walai S, Al-Sadi S, Fredriksson R . Histological analysis of SLC38A6 (SNAT6) expression in mouse brain shows selective expression in excitatory neurons with high expression in the synapses. PLoS One. 2014; 9(4):e95438. PMC: 3994050. DOI: 10.1371/journal.pone.0095438. View

5.
Singh K, Tanui R, Gameiro A, Eisenberg G, Colas C, Schlessinger A . Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2. Bioorg Med Chem Lett. 2017; 27(3):398-402. PMC: 5363072. DOI: 10.1016/j.bmcl.2016.12.063. View